SHOCK developing in the course of acute myocardial infarction is an ominous event with a guarded prognosis. The outcome can be improved with the use of vasopressor agents,"2 but the manner in which they modify the hemodynamic derangement in man has not been studied extensively. [3] [4] [5] [6] [7] It is difficult to produce an experimental model simulating the syndrome of "cardiogenic shock" as seen in man. 8 For this reason additional studies of the naturally occurring syndrome are needed. With portable recording apparatus, hemodynamic studies can be conducted at the bedside without detriment to the patient; repeated measurements can be made, and the effects of therapy can be immediately evaluated. Each patient can serve as his own control, and by adding a single rapidly acting agent at a time and obtaining repeated measurements, the effectiveness of a therapeutic program can be determined.
In this study patients with acute myocardial infarction with and without shock were evaluated. The relative importance of diminished cardiac output and alterations in systemic vascular resistance in the genesis of the shock syndrome were further defined by first increasing the systemic vascular resistance with an agent which is essentially a pure vasoconstrictor (methoxamine) and then in- From creasing cardiac output while maintaining vasoconstriction by infusing an agent which has, in addition, an inotropic effect (norepinephrine) .9 10 The importance of a therapeutic program correcting these determinants of arterial pressure was assessed.
Methods Shock was presumed to be present if there was: (1) a decrease in the blood pressure to below 80 mm Hg systolic (or below 90 mm Hg systolic in a known hypertensive), and (2) clinical evidence of shock such as low volume pulse, dulled sensorium, sweating, cyanosis, and pallor. The presence of acute myocardial infarction was established by unequivocal electrocardiographic evidence of recent infarction using the standard 12-lead scalar electrocardiogram. Twenty-three patients with myocardial infarction were studied, and 12 of these were in shock at the time of the study.
The average age of the 11 patients with recent myocardial infarcts who were not in shock was 58 years and varied between 40 and 85 years. Ten were male. Five died during their hospital stay, and six recovered.
The average age of the 12 patients with recent myocardial infarcts associated with shock was 66 years, the youngest being 45 and the oldest 86 (table 1) . Seven were males. Seven of the patients in shock died within 16 
Results

Control Data
Myocardial Infarction without Shock (11 Patients) The mean cardiac output in these patients was 3.8 ± 1.5 L/min, the mean arterial mean pressure, 92 + 23 mm Hg, and the mean systemic vascular resistance, 26+ 9 mm Hg/L/ min (table 2) . Two of these patients were Mean aortic pressurecentral venous pressure SVR C
Cardiac output
When studies were initiated, vasopressors were discontinued until the aortic pressure restabilized at shock levels. Basic control records of pressure pulses and indicator-dilution curves were obtained. If the patient met the criteria for shock and after control records were obtained, methoxamine (0.5 mg/ml) was infused until systolic pressure was more than 100 mm Hg or until a maximum of 80 mg had been given. Indicator The mean cardiac output was 2.2 + 0.9 L/min. The mean arterial pressure was 53 + (table 3) . The patients were arbitrarily divided into those with high systemic vascular resistances (more than 20 mm Hg/L/min), group A, and those with low systemic vascular resistances (less than 20 mm Hg/L/min), group B. There was no difference between the two groups in the length of time these patients had been in shock prior to the study.
Results of Drug Infusion
Methoxamine was given to seven patients (table 4). Four of these showed a significant (greater than 5%) decrease in cardiac output which varied between 19% and 28% of the control level, and three showed no significant change. Although the mean arterial pressure was increased between 3% and 110% in six, it reached adequate levels (above 80) in only two patients. One patient had a 14% decrease in mean arterial pressure. The central venous pressure was increased 1.0 mm Hg in one, fell 5.0 mm Hg in one, and was essentially unchanged in four. The systemic vascular resistance was increased in all pa-Circulation, Volume XXXIII, May 1966 tients, and the increase varied between 9% and 212% of the control level. Norepinephrine was given to 11 patients, seven of whom had received methoxamine (table 5). Cardiac output was increased in all except one; it varied between -8% and +57% of control levels. Mean aortic pressure was increased in all, and the increase varied between 3% and 175% of the control, although the pressure did not go above 80 mm Hg in four patients. All four died within 8 hours of the onset of shock. The central venous pressure was measured in nine patients; it was increased 1 to 3 mm Hg in four, decreased 1.0 and 0.7 mm Hg in two, and remained the same in three. The systemic vascular resistance was increased from 6% to 101% over control levels in 10 patients and was decreased 20% in one patient.
Low viscosity dextran was given to two patients and resulted in a 14% and a 54% in-Circulation, Volume XXXIII, May 1966 crease in cardiac output with no change in mean aortic pressure. The central venous pressure rose 2.3 and 7.0 mm Hg, respectively.
Discussion
Gilbert and associates12 were the first to measure the cardiac output in patients with myocardial infarction with shock. Freis13 and Smith14 and their associates in similar studies also demonstrated decreases in cardiac output, but in all these studies, the response of the calculated systemic vascular resistance varied. Subsequent studies of acute myocardial infarction with shock have not shown a consistent change in the peripheral vascular resistance.3-7' [15] [16] [17] [18] [19] By micro-embolization of the coronary arteries of the dog, Agress and Binder20 have produced a syndrome resembling shock as seen in myocardial infarction in man and demonstrated an inappropriately small rise in systemic vascular resistance accompanying the decrease in cardiac output. In these animals it was possible to ameliorate the syndrome of "shock" by vagotomy and dorsal sympathectomy. They postulated that these procedures blocked reflex inhibition of an "appropriate" vasoconstrictor response.
In the present series of patients with myocardial infarction, the shock group differed from the nonshock group in having a lower mean cardiac output (P < 0.01), although there were no statistically signifi- cant differences between the groups in the means of the systemic vascular resistances or central venous pressures. Six (group B) of the 12 patients in shock, however, had systemic vascular resistances of less than 20 mm Hg/L/min, whereas only two of the 11 patients not in shock had systemic vascular resistances-of less than 20 mm Hg/L/min. Of the six patients with systemic -vascular resistances of more than 20 (group A), one patient died before any therapy could be Circulation, Volume XXXIII, May 1966 given. Of the five remaining patients, three were given methoxamine, and all were given norepinephrine. In each the systemic vascular resistance increased with methoxamine, but cardiac output fell. Methoxamine did not bring arterial pressures above a mean of 80 in any of these patients. In one of these patients (H. J.) arterial pressure did not increase above 80 with norepinephrine despite an increase in cardiac output; in the other two this level of pressure was achieved with norepinephrine, but this achievement was due entirely to an increase in cardiac output without further increase in vascular resistance.
The two patients given norepinephrine alone showed increases in calculated systemic vascular resistances as well as cardiac outputs, but one did not achieve an adequate pressure and died 3 hours after the onset of shock. The other patient was the only one in the entire series to recover and be sent home. He had the highest cardiac output and lowest resistance in this group.
Of these five patients, then, all could increase the systemic vascular resistance and cardiac output, but only one could be taken off vasopressors.
Of the six "shock" patients with relatively low systemic vascular resistances (group B), four were given methoxamine, and two of these responded with adequate increases in arterial pressure and systemic vascular resistance. These changes, however, were associated with a fall in cardiac output and lack of clinical improvement despite the return of blood pressure to normal levels. The systemic vascular resistances of the other two patients in this group who were given methoxamine were not raised above 20 mm Hg/L, and their mean arterial pressures did not rise above shock levels. Neither of these latter patients responded sufficiently to norepinephrine, and both died in 8 hours or less of admission and within 4 hours of the start of the study. An inadequate vasoconstrictor response to these sympathomimetic agents suggests vasomotor paralysis secondary to anoxia rather than reflex inhibition.2'
The two patients in shock with relatively Circulation, Volume XXXIII, May 1966 low systemic vascular resistances who were not given methoxamine but were given norepinephrine responded adequately with increases in systemic vascular resistances, cardiac outputs, and arterial blood pressures. In these two patients and also in the two with low resistances responding to methoxamine, vasoconstriction must not have been maximal prior to infusions despite low arterial pressures. Since they responded to vasopressors, it seems likely that their inadequate vascular responses to the hypotension of "cardiogenic shock" was not due to anoxia but rather that it more closely resembled the reflex inhibition of vasoconstriction described by Agress and Binder.20 Three of the four patients with low resistance who responded to vasopressors recovered from shock and could be taken off vasopressor therapy, but they died later in their hospital course of other complications of their heart disease. In normal subjects norepinephrine elevates the blood pressure by increasing systemic vascular resistance, but this change is associated with reflex slowing of the heart rate and either no change or a decrease in cardiac output.22 Two of our patients with acute myocardial infarction who were not in shock responded to norepinephrine with a decrease in cardiac output. Patients who were in shock, however, responded with significant increases in cardiac output which suggests that the baroreceptors were not stimulated to decrease the cardiac output at aortic systolic pressure levels of 110 mm Hg or less.23 When arterial pressures were increased above 110 low aortic pressures. This is consistent with the concept that the coronary arterial system is maximally vasodilated in patients with arteriosclerotic heart disease,25 Under these conditions coronary blood flow is pressure-dependent rather than autoregulatory, as in the normal individual,26 and the maintenance of an adequate aortic pressure is extremely important.
Low viscosity dextran was given to two of our patients at the end of the study and appeared to increase the cardiac output and decrease the systemic vascular resistance of patients who had been receiving pressor agents for some hours. The prolonged use of pressor agents could have produced a condition similar to epinephrine shock-a loss of vasomotor responsiveness due to peripheral stasis.27 One patient who received low molecular weight dextran showed a good increase in cardiac output after the relatively low central venous pressure was raised. The fact that this patient was the one long-term survivor may speak more for the integrity of the myocardium than the efficacy of low viscosity dextran in the therapy of acute myocardial infarction. Nevertheless, in patients with low central venous pressures, and particularly those with vasomotor unresponsiveness to vasopressors, further attempts should be made to determine whether volume expansion may increase cardiac output and restore responsiveness to vasopressor agents. The hypotensive patient, who has been treated with vasopressors for a long period, is clinically out of shock, and has a low central venous pressure should be given volume expanders during the attempt to reduce the dose of vasopressor agent. We have done this successfully in one patient not reported in this series.
These data indicate that the treatment of choice for myocardial infarction with shock should include use of a vasopressor agent such as norepinephrine which has both vasoconstrictor and inotropic action. The inotropic action of the drug appears to be important, since merely raising the blood pressure by incre-asing systemic vascular resistance is ac-companied by a significant decrease in cardiac output. The vasoconstrictor activity is important in those patients who have an inappropriately small rise in systemic vascular resistance. The mean aortic pressure must be raised to ensure an adequate coronary perfusion pressure. We have been reluctant to give isopropyl norepinephrine, since it lowers systemic vascular resistance and may not increase the blood pressure. Since coronary flow is dependent upon central aortic pressure,28 it would seem that the patient with a compromised coronary artery lumen should not be subjected to increase in the oxygen requirements of the myocardium without providing adequate coronary perfusion pressure.
The arterial systolic pressure should be raised to between 100 and 110 mm Hg, but not above this in the normotensive individual, since raising the pressure above this level tends to decrease cardiac output by a reflex mechanism.7' 29 Summary and Conclusions Twenty-three patients with recent myocardial infarctions were studied at the bedside. Twelve were in shock. Comparison of the group in shock with the group not in shock revealed that the shock group differed from the nonshock group in having a lower mean cardiac output as well as a lower mean aortic pressure. Although there was no significant difference in the means of the calculated systemic vascular resistances in the two groups, six (50%) of the patients in shock had systemic vascular resistances of less than 20 mm Hg/L/min, while only two (18%) of those not in shock had such low systemic vascular resistances.
Attempts to increase the systemic vascular resistance with methoxamine elevated the mean aortic pressure to more than 80 mm Hg in only two of seven patients and resulted in a decline in cardiac output in all. Thus, raising the systemic vascular resistance alone did not improve the condition of the patient.
In two patients the systemic vascular resistance did not increase to more than 20 mm Hg/L/min following administration of either Circulation, Volune XXXIII, May 1966 methoxamine or norepinephrine. These two patients may represent a group with vasomotor unresponsiveness of the peripheral circulation due to anoxia or the acidosis associated with anoxia.
Four of six patients in shock with systemic vascular resistances of less than 20 mm Hg/ L/min responded to methoxamine and norepinephrine by increases in systemic vascular resistance and presumably represent a group in which there was an inappropriate vasomotor response to a drop in cardiac output. Norepinephrine infusion resulted in increased cardiac outputs in patients with shock due to myocardial infarction and is, therefore, preferable to a pure vasoconstrictor such as methoxamine.
